Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GLMD Galmed Pharmaceuticals
0.346
-0.025-6.79%
Post Mkt Price
0.357
+0.0108+3.12%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
-56.13% 22.4M -51.12% 28.74M -31.58% 34.82M -31.58% 34.82M
-Cash and cash equivalents
-75.01% 1.98M -72.05% 3.74M -58.49% 2.88M -58.49% 2.88M
-Short-term investments
-52.66% 20.42M -44.96% 25M -27.33% 31.93M -27.33% 31.93M
Receivables
26.08% 614K 7.53% 843K 19.7% 79K 38.55% 1.13M
-Other receivables
26.08% 614K 7.53% 843K 19.7% 79K 38.55% 1.13M
Prepaid assets
-- -- -- -- 40.21% 1.05M -- --
Restricted cash
0.88% 114K 0.88% 114K 0.88% 114K 0.88% 114K
Total current assets
-55.23% 23.13M -50.25% 29.7M -30.41% 36.05M -30.41% 36.05M
Non current assets
Net PPE
-32.58% 445K -26.37% 497K -3.33% 551K -3.33% 551K
-Gross PPE
-32.58% 445K -26.37% 497K 1.48% 1.51M -3.33% 551K
-Accumulated depreciation
-- -- -- -- -4.48% -957K -- --
Total non current assets
-32.58% 445K -26.37% 497K -3.33% 551K -3.33% 551K
Total assets
-54.95% 23.58M -49.99% 30.2M -30.12% 36.61M -30.12% 36.61M
Liabilities
Current liabilities
Payables
-61.06% 2.73M -20.88% 5.65M -26.62% 5.88M -26.62% 5.88M
-accounts payable
-62.89% 2.09M -16.68% 4.84M -30.87% 4.87M -30.87% 4.87M
-Other payable
-53.59% 640K -39.13% 812K 4.35% 1.01M 4.35% 1.01M
Current liabilities
-61.06% 2.73M -20.88% 5.65M -26.62% 5.88M -26.62% 5.88M
Non current liabilities
Long term debt and capital lease obligation
-57.86% 134K -35.34% 183K 6.02% 229K 6.02% 229K
-Long term capital lease obligation
-57.86% 134K -35.34% 183K 6.02% 229K 6.02% 229K
Total non current liabilities
-57.86% 134K -35.34% 183K 6.02% 229K 6.02% 229K
Total liabilities
-60.92% 2.86M -21.43% 5.83M -25.77% 6.11M -25.77% 6.11M
Shareholders'equity
Share capital
0% 70K 0% 70K 20.69% 70K 20.69% 70K
-common stock
0% 70K 0% 70K 20.69% 70K 20.69% 70K
Retained earnings
-16.37% -178.05M -20.54% -174.32M -23.92% -168.17M -23.92% -168.17M
Paid-in capital
0.93% 199.68M 0.95% 199.23M 10.72% 198.77M 10.72% 198.77M
Gains losses not affecting retained earnings
-1009.26% -982K -533.8% -616K -162.87% -171K -162.87% -171K
Total stockholders'equity
-53.97% 20.71M -53.99% 24.37M -30.93% 30.5M -30.93% 30.5M
Total equity
-53.97% 20.71M -53.99% 24.37M -30.93% 30.5M -30.93% 30.5M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Baharaff, Allen
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top